The radiation response of androgen-refractory prostate cancer cell line C4-2 derived from androgen-sensitive cell line LNCaP

Asian Journal of Andrology

Volumn 12, Issue 3, 2010, Pages 405-414

  Xie, Bang Xiang ^a,b   Zhang, Hui ^a   Yu, Lan ^a   Wang, Jian ^a   Pang, Bo ^a   Wu, Rui Qin ^a   Qian, Xiao Long ^a   Li, Shan Hu ^a   Shi, Qing Guo ^a   Wang, Le Le ^a   Zhou, Jian Guang ^a  

^a BEIJING INSTITUTE OF BIOTECHNOLOGY   (China)

^b CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

C4 2; LNCaP; Prostate cancer; Radiation response

Indexed keywords

ANDROGEN;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL STRAIN C4 2; CELL STRAIN LNCAP; CELL SURVIVAL; CELL VIABILITY; CLONOGENIC ASSAY; CONTROLLED STUDY; DNA REPAIR; GENE EXPRESSION; PROSTATE CANCER; RADIATION RESPONSE; RADIOSENSITIVITY;

ADENOCARCINOMA; ANDROGENS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; DNA REPAIR; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, CDC; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; RADIATION TOLERANCE; TETRAZOLIUM SALTS; THIAZOLES;

EID: 77952042528     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2009.91     Document Type: Article

References (28)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, et al. Cancer Statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Cooperberg MR, Broering JM, Litwin MS, Lubeck DP, Mehta SS, et al. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate urologic research endeavor (CapSURE), a national disease registry. J Urol 2004;171:1393-401.
3. Zelefsky MJ, Ben-Porat L, Chan HM, Fearn PA, Venkatraman ES. Evaluation of postradiotherapy PSA patterns and correlation with 10-year disease free survival outcomes for prostate cancer. Int J Radiat Oncol Biol Phys 2006;66:382-8.
4. Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002;53:1097-105.
5. Rosen EM, Fan SJ, Rockwell S, Goldberg ID. The molecular and cellular basis of radiosensitivity: implications for understanding how normal tissues and tumors respond to therapeutic radiation. Cancer Invest 1999;17:56-72.
6. Lee AK. Radiation therapy combined with hormone therapy for prostate cancer. Semin Radiat Oncol 2006;16:20-8.
7. Wu CT, Chen WC, Liao SK, Hsu CL, Lee KD, et al. The radiation response of hormone resistant prostate cancer induced by long-term hormone therapy. Endocr Relat Cancer 2007;14:633-43.
8. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, et al. LNCaP model of human prostatic carcinoma. Cancer Res 1983;43:1809-18.
9. Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, et al. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 1994;54:2577-81.
10. Wu HC, Hsieh JT, Gleave ME, Brown NM, Pathak S, et al. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int J Cancer 1994;57:406-12.
11. Scardino PT, Wheeler TM. Local control of prostate cancer with radiotherapy: frequency and prognostic significance of positive results of postirradiation prostate biopsy. NCI Monogr 1988;7:95-103.
12. Crook JM, Perry GA, Robertson S, Esche BA. Routine prostate biopsies following radiotherapy for prostate cancer: results for 226 patients. Urology 1995;45:624-31.
13. Zelefsky MJ, Leibel SA, Gaudin PB, Kutcher GJ, Fleshner NE, et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 1998;41:491-500.
14. Isaacs JT. The biology of hormone refractory prostate cancer. Uro Clin North Am 1999;26:263-73.
15. Kaliks RA, Giglio AD. Management of advanced prostate cancer. Rev Assoc Med Bras 2008;54:178-82.
16. Wo JY, Zietman AL. Why does androgen deprivation enhance the results of radiation therapy? Urol Oncol 2008;26:522-9.
17. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007;26:1324-37.
18. Letai A, Sorcinelli MD, Beard C, Korsmeyer SJ. Antiapoptotic BCL-2 is required for maintenance of a model leukemia. Cancer Cell 2004;6:241-9.
19. Cimprich KA, Cortez D. ATR: an essential regulator of genome integrity. Nat Rev Mol Cell Biol 2008;9:616-27.
20. Cortez D, Guntuku S, Qin J, Elledge SJ. ATR and ATRIP: partners in checkpoint signaling. Science 2001;294:1713-6.
21. Abraham RT. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev 2001;15:2177-96.
22. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998;282:1497-501.
23. 2/M checkpoint. Genes Dev 2000;14:1584-8.
24. Scott SL, Earle JD, Gumerlock PH. Functional p53 increases prostate cancer cell survival after exposure to fractionated doses of ionizing radiation. Cancer Res 2003;63:7190-6.
25. Sarkaria JN, Busby EC, Tibbetts RS, Roos P, Taya Y, et al. Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res 1999;59:4375-82.
26. 2 checkpoint abrogators. Curr Med Chem Anticancer Agents 2003;3:35-46.
27. Paull TT. New glimpses of an old machine. Cell 2001;107:563-5.
28. Paull TT, Gellert M. Nbs l potentiates ATP-driven DNA unwinding and endonuclease cleavage by the Mre11/Rad50 complex. Genes Dev 1999;13:1276-88.